Merck Reiterates Confidence in Returning to Sustainable Growth

Tailwind thanks to robust global growth trends in all three business sectors

18-Oct-2024 - Merck is looking confidently toward the future. At the Capital Markets Day, the company shared its expectation of profitable and financially strong growth in the coming years. After the transitional year of 2023, Merck considers the medium-term growth opportunities in its markets to be intact. ...

Merck Signs Definitive Agreement to Acquire Life Science Company Mirus Bio for US$ 600 million

"This strategic acquisition is a further building block for accelerating growth in the break-through technologies of the future"

24-May-2024 - Merck has signed a definitive agreement to acquire life science company Mirus Bio for US$600million (around €550million). Based in Madison, Wisconsin, USA, Mirus Bio is a specialist in the development and commercialization of transfection reagents. Transfection reagents, such as Mirus Bio's ...

Merck and Japanese start-up launch collaboration

Both companies to accelerate development and manufacturing of viral vector-based gene therapy applications

15-Dec-2022 - Merck has signed a non-binding Memorandum of Understanding (MoU) with Synplogen, a startup spun out of Kobe University's Graduate School of Science, Technology and Innovation. Both companies aim to integrate their capabilities to provide streamlined development, manufacturing and testing for ...

Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy

Growth through investments in the “Big 3”

13-Oct-2021 - Merck announced the opening of its second Carlsbad, California-based facility, significantly expanding its global CDMO footprint. This new €100 million, 140,000-square foot facility will more than double the company’s existing capacity to support large-scale commercial and industrial ...

Merck Boosts Commercial Viral Vector and Gene Therapy Manufacturing Capacity

New, € 100 million facility will more than double existing production capacity

22-Apr-2020 - Merck announced a second Carlsbad, California, U.S.A.-based facility for its BioReliance® viral and gene therapy service offering. The new, €100 million commercial facility is expected to open next year. “Viral vector manufacturing has transitioned from a niche industry to the cornerstone of the ...

Japan and Singapore Grant CRISPR Patents to Merck

27-Nov-2019 - Merck announced that the Japan Patent Office and the Intellectual Property Office of Singapore have each allowed the company’s patent application for the use of paired CRISPR nickases, bringing Merck’s number of patents to 22 worldwide. “Paired nickases represent a significant step in increasing ...

Merck Becomes the First to Use Acoustic Technology for Cell Therapy Manufacturing

Acquisition of FloDesign Sonics marks next step in autologous manufacturing

11-Oct-2019 - Merck announced it has acquired FloDesign Sonics, of Wilbraham, Massachusetts, USA, developer of a unique acoustic cell processing platform for the industrialization of cell and gene therapy manufacturing. Financial details were not disclosed. “Chimeric antigen receptor T cell therapies, or CAR-T ...

Merck To Collaborate with GenScript to Accelerate Cell and Gene Therapy Industrialization in China

Collaboration to build global-standard platform for plasmid and virus manufacturing in China

20-Mar-2019 - Merck announced the signing of a non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on plasmid and viral vector manufacturing. “Manufacturing of high-quality plasmid and viral vectors is one of the most critical components in the ...